Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  gefitinib
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 54 for your search:
Start Over
Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: AIO-TRK-0214, 2014-005595-28, IISR ESR-14-10598, NCT02326285
Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ShanghaiChest Hospital, NCT02338011
Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: PekingUTH-LL01, NCT02350361
Gefitinib Combined With Thalidomide to Treat NSCLC
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: Over 18 to less than 75
Sponsor: Other
Protocol IDs: GELI, NCT02387086
Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ZhejiangCH06, NCT01158170
Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: C-TONG 1104, NCT01405079
Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CTONG 1102, NCT01404260
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5160C00007, 2014-002694-11, NCT02296125
Hydroxychloroquine and Gefitinib to Treat Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: NS 01/03/08, 2008/00196, NCT00809237
Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GECP10-03, 2010-024178-21, NCT01513174
MSC2156119J With Gefitinib in Subjects With Advanced Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 200095-006, NCT01982955
Selumetinib in Combination With Gefitinib in NSCLC Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: 201312070MIPC, NCT02025114
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3475-021, NCT02039674
Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000582623, YONSEI-4-2006-0136, ZENECA-YONSEI-4-2006-0136, 4-2006-0136, NCT00616499
Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: Iressa combined with Pem/Cis, NCT01192243
Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 70 to 85
Sponsor: Other
Protocol IDs: ZhejiangCH10, NCT01291823
Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-07-252, NCT01312337
Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CS-S10-09, NCT01391260
Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib
Phase: Phase II
Type: Diagnostic, Tissue collection/Repository, Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: P01425, 2010-023355-29, 11/H0304/8, NCT01405846
Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: SVH-1, NCT01485809
Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: NCCCTS-11-581, NCT01502202
First Line Gefitinib by FDG-PET Metabolic Response
Phase: Phase II
Type: Treatment
Status: Active
Age: 19 and over
Sponsor: Other
Protocol IDs: AMC 2011-0858, NCT01510990
Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IFCT-1003, NCT01556191
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CINC280X2202, 2011-002569-39, NCT01610336
Start Over